Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

el and selective adenosine2a receptor antagonist for Parkinson's disease (completing Phase II); results of a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease were reported showing that preladenant met the primary endpoint.

Presenters reviewed a range of other therapies in various stages of development in the company's six therapeutic areas: allergy/respiratory; cardiovascular/metabolic; central nervous system; immunology/infectious disease; oncology; and women's health.

Several earlier-stage research projects were also unveiled for the first time, including:

  • Two monoclonal antibodies for oncology -- robatumumab (anti-IGF-1R) in Phase II and anti-HGF in Phase I;
  • Two projects for Alzheimer's -- a beta secretase inhibitor and a gamma secretase inhibitor; and
  • A novel anti-inflammatory agent, anti-IL-23, in Phase I for chronic inflammatory conditions.

In Animal Health, the company highlighted its global leadership position and diverse portfolio and pipeline, with more than 120 small-molecule projects and 140 biological projects under way. The company also highlighted three growth corridors for Schering-Plough: companion animal; parasiticides; and geographic expansion in the U.S., Japan and emerging markets.

Webcast Information

A replay of the webcast of Schering-Plough's "R&D Update" meeting is available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. The replay will be available starting on Nov. 24 through 5 p.m. on Dec. 24.

Disclosure Notice

DISCLOSURE NOTICE:
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Scientific Corporation (NYSE: BSX ) today announced ... Connors as a Director. ,, Ms. Connors, ... division of Tyco International. Previously, she served as ... operations and general management. Prior to Eaton, Ms. ... management capacities with Ford, Chrysler and Mogami Denki, a ...
(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...
(Date:12/16/2009)... Greenway Medical Technologies, Inc. today announced that its ... management and interoperability solution, Prime Suite® 2011, ... annual 2009 Top 20 Best in KLAS ... ,, For practices having between six and 25 ... in KLAS in ambulatory EMR for the fourth ...
Breaking Medicine Technology:Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3CareCentrix Receives URAC Health Utilization Management Accreditation 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock 5303 1Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock 5303 2CPhI 2009 3A Madrid Launch for BioPh Marks Pharma and Biotech Convergence 5300 1CPhI 2009 3A Madrid Launch for BioPh Marks Pharma and Biotech Convergence 5300 2CPhI 2009 3A Madrid Launch for BioPh Marks Pharma and Biotech Convergence 5300 3Lab on a Chip Might Speed Breast Cancer Monitoring 59092 1Lab on a Chip Might Speed Breast Cancer Monitoring 59092 2Lab on a Chip Might Speed Breast Cancer Monitoring 59092 3
... WIRE)--May 24, 2007 - Inovio Biomedical,Corporation (AMEX:INO), ... for cancers and infectious diseases and a ... announced today,that interim clinical trial results demonstrated ... technology was,safe and tolerable, facilitated gene expression, ...
... - Findings from an Otsuka Pharmaceutical Co, ... Association Annual Meeting -, SAN DIEGO, May ... study in,adolescents (13- 17 years old) with ... Squibb Company atypical,antipsychotic aripiprazole demonstrated significant improvement,compared ...
Other Medicine Technology:Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 2Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 3Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 4Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 5Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 2Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 3Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 4Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 5Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 6Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 7Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 8Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 9
(Date:12/17/2009)... Dec. 17 Neurocrine Biosciences, Inc. (Nasdaq: ... a privately negotiated transaction to sell an aggregate of ... of Venrock at a price of $2.09 per share, ... million. Neurocrine expects the financing to close on or ... ,, A shelf registration statement relating to ...
(Date:12/17/2009)... 17 Abaxis, Inc. (Nasdaq: ABAX ... analysis instruments and rapid tests for the medical, ... has entered the production animal diagnostics marketplace with ... Test. This is a USDA-licensed test for Avian ... and ducks. The disposable, non-instrumented device, providing results ...
(Date:12/17/2009)... PricewaterhouseCoopers, Health Research Institute,s Top 10 Health Industry ... control at the head of the list as the ... typically lags trends in the business cycle by a ... new growth for other sectors of the U.S. economy, ... Chin, M.D., partner and leader of PricewaterhouseCoopers, Health Research ...
(Date:12/17/2009)... provide alternative natural relief prior to considering drugs. , ... ... 2009 -- D-Psoria products are the first topical, ... severe skin conditions . Developed by Astrel Genome ... MediNiche Pharmaceuticals, St. Louis, Missouri., , ,D-Psoria products were ...
(Date:12/17/2009)... Stauffer & Nathan law firm, litigators of complex personal injury and ... , ... Tulsa, OK (Lexis Nexis) December 17, 2009 ... than 20 years of experience handling personal injury and insurance coverage ... of the top attorneys in the state of Oklahoma for 2009-2010., ...
Breaking Medicine News(10 mins):Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 3Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 4Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 2Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 3Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 4Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 5Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 6Health News:Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010 7Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2
... a metabolic physiologist at the University of Sherbrooke, Quebec said ... fuelled and provided the essential nutrients to make our brains ... process of brain expansion by eating clams, frogs, bird eggs ... to the explosive brain growth. Our brains weigh roughly twice ...
... anthropology in Arts & Sciences at Washington University in St. ... actually peace loving race in earlier times. // Sussman made ... the Menu," during the American Association for the Advancement of ... ,In his new book "Man the ...
... Chronic Wasting Disease (CWD) in Alberta led to the killing of ... area. This is an effort to curb the spread of chronic ... Ealey said that these measures can prevent the spread of the ... deer among high-risk areas is virtually the only way to reduce ...
... University of Jerusalem researchers report that another health benefit of ... a result it reduces the incidence of heart disease. // ... eat one grapefruit daily can significantly reduce the levels of ... not eat the fruit. This study is relevant in the ...
... the forefront of the mission to translate discoveries in basic ... 13 schools to have been chosen to receive a collective ... ,"The gap between basic biology and medical practice ... and education at the School of Medicine and principal investigator ...
... to possess strong anti-tumor properties in studies conducted on ... cancer patients. // The compound has been found to ... by enhancing the function of enzymes that remove toxins ... been published in the journal Cancer Research. ...
Other Medicine News:Health News:Mystery behind the evolution of the Human brain 2Health News:Early Man Was A Prey Rather Than A Predator 2Health News:One fruit that has captured the health benefit sector is Grapefruit! 2Health News:Getting Basic Science to Work For Medicine 2Health News:New Compound Offers Hope In Liver Cancer Treatment 2
Inquire...
... Software is easy to configure ... any balance. Use the standard method or ... volume, temperature, pressure, etc.) QualiTrace automatically manages ... the measurements from the balance to the ...
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile...
Reagent Basin, 60mL, 5/Box...
Medicine Products: